Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
You may also be interested in...
The diagnostics company said the test is scheduled for US launch in Q4 2020.
Qiagen's shareholders said Thermo Fisher's final offer price for the diagnostics company was too low.
Beiersdorf and former owner Bayer are on the verge of settling a proposed class action in California’s Northern District challenging “mineral-based” claims on Coppertone sunscreens that also contain chemical UV filters. However, the parties will have to try again with their proposed terms.